Share your CIDP experience with your neurologist. Download the VYVGART Hytrulo Doctor Discussion Guide, featuring an easy-to-use tool that can help you track your symptoms and abilities, so you can have meaningful conversations with your doctor about your CIDP treatment.
Explore the effectiveness and safety data, learn about dosing, and find much more in this informative brochure.
Learn more about My VYVGART Path, the Patient Support Program that has friendly and knowledgeable Nurse Case Managers to support you on your VYVGART Hytrulo treatment journey.
See if you could be eligible to pay as little as $0 for your co-pay through the VYVGART Hytrulo Co-Pay Program.*
*Eligible commercially insured patients may pay as little as $0 for VYVGART Hytrulo and may receive a maximum benefit of $25,000 per calendar year for their eligible out-of-pocket costs for the drug and drug administration. Persons residing in MA and RI are not eligible for financial assistance related to administration costs. Please see full Terms and Conditions.
Already have a VYVGART Hytrulo prescription? Fill out the patient enrollment form to enroll yourself in My VYVGART Path.
Gain a better understanding of the insurance process and learn how the team at My VYVGART Path may assist you in accessing VYVGART Hytrulo.
Get information about dosing and how to prepare for your VYVGART Hytrulo subcutaneous injection.
Use this card to share treatment information and key contacts in case of emergency.
This milestone virtual event explored VYVGART Hytrulo, the first innovation in CIDP treatment in over 30 years.
Find answers to common questions about VYVGART Hytrulo treatment and support.
CIDP=chronic inflammatory demyelinating polyneuropathy
Do not use VYVGART HYTRULO if you have a serious allergy to efgartigimod alfa, hyaluronidase, or any of the other ingredients in VYVGART HYTRULO. VYVGART HYTRULO can cause serious allergic reactions and a decrease in blood pressure leading to fainting.
Tell your doctor if you have signs or symptoms of an infection, allergic reaction, or infusion-related reaction. These can happen while you are receiving your VYVGART HYTRULO treatment or afterward. Your doctor may need to pause or stop your treatment. Contact your doctor immediately if you have signs or symptoms of a serious allergic reaction.
The most common side effects in efgartigimod-alfa-fcab-treated patients were respiratory tract infection, headache, and urinary tract infection. Additional common side effects with VYVGART HYTRULO are injection site reactions, including rash, redness of the skin, itching sensation, bruising, pain, and hives.
These are not all the possible side effects of VYVGART HYTRULO. Call your doctor for medical advice about side effects. You may report side effects to the US Food and Drug Administration at 1-800-FDA-1088.
VYVGART HYTRULO is a prescription medicine used for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP)
Do not use VYVGART HYTRULO if you have a serious allergy to efgartigimod alfa, hyaluronidase, or any of the other ingredients in VYVGART HYTRULO. VYVGART HYTRULO can cause serious allergic reactions and a decrease in blood pressure leading to fainting.
Tell your doctor if you have signs or symptoms of an infection, allergic reaction, or infusion-related reaction. These can happen while you are receiving your VYVGART HYTRULO treatment or afterward. Your doctor may need to pause or stop your treatment. Contact your doctor immediately if you have signs or symptoms of a serious allergic reaction.
The most common side effects in efgartigimod-alfa-fcab-treated patients were respiratory tract infection, headache, and urinary tract infection. Additional common side effects with VYVGART HYTRULO are injection site reactions, including rash, redness of the skin, itching sensation, bruising, pain, and hives.
These are not all the possible side effects of VYVGART HYTRULO. Call your doctor for medical advice about side effects. You may report side effects to the US Food and Drug Administration at 1-800-FDA-1088.
VYVGART HYTRULO is a prescription medicine used for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP)